EP4076339A1 - Composition ou dispositif médical comprenant des polymères à base d'oligo(éthylène glycol) - Google Patents
Composition ou dispositif médical comprenant des polymères à base d'oligo(éthylène glycol)Info
- Publication number
- EP4076339A1 EP4076339A1 EP20824611.6A EP20824611A EP4076339A1 EP 4076339 A1 EP4076339 A1 EP 4076339A1 EP 20824611 A EP20824611 A EP 20824611A EP 4076339 A1 EP4076339 A1 EP 4076339A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mass
- water
- mole
- soluble polymer
- films
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
Definitions
- composition or medical device comprising polymers based on oligo (ethylene glycol)
- the present invention relates to a cosmetic, a pharmaceutical composition or a medical device for topical application or on mucous membranes, said composition comprising the combination of a polymer based on oligo (ethylene glycol) crosslinked in the form of an aqueous dispersion of colloidal particles of microgels and of a polymer based on oligo (ethylene glycol) soluble in water.
- the invention also relates to a process for the preparation of this composition.
- compositions based on poly (oligo- (ethylene glycol) methacrylate) microgels make it possible to achieve this object.
- aqueous dispersions of such microgels has been described in the literature, in particular in patent applications WO 2016/110615 and WO 2019/077404, and the publications Boularas et al., Polymer Chem., 2016, 7 , 350-363; and Aguirre et al., Polymer Chem., 9, 1155-1159.
- a side product is formed which consists of a water soluble polymer (WSP), cited as a free polymer.
- the mixing of the purified microgels with the free polymer makes it possible to control and control the value of the viscoelastic modulus of the films without reducing the elongation at break.
- the free polymer makes it possible to increase the adhesion of a film of microgels without modifying its mechanical properties.
- the films obtained by drying the combination of the microgels and the free polymer exhibit particular mechanical properties of elasticity and tack.
- the inventors have surprisingly found that these properties can be modulated as a function of the microgel-polymer mass ratio.
- the inventors have discovered that the chemical composition of the free polymer is very comparable to that of microgels and allows good compatibility between the two components.
- the branched and crosslinked structure allows the preservation of the resistance to stretching of films obtained from their mixtures.
- the self-assembly of the microgel / polymer mixture forms a film with promising mechanical properties for skin applications: the elastic modulus is low, the deformability capacity is high and the elongation at break high. Reformulation with the free polymer potentially makes it possible to control and control the value of the viscoelastic modulus of the films without reducing the elongation at break.
- microgel films with adjustable mechanical properties have never been reported in the literature.
- the variation in the rheological properties of the films is directly obtained by virtue of a secondary synthesis product, the free polymer.
- This has the same chemical composition as the microgels and therefore has excellent compatibility with the latter. This has the advantage of not weakening the self-assembled network of the microgels, which results in the retention of resistance to stretching.
- the addition of the free polymer can induce a variation of the real part of the complex shear modulus (G) between lxlO 3 and lxlO 5 Pa. This makes it possible to obtain films having a very pronounced tack up to films not showing any tackiness at all.
- the elongation at break which reflects the cohesion of the microgel network at very large deformations, does not decrease with the addition of free polymer.
- the structural characterization of the free polymer by aqueous chromatography reveals a very branched polymer resembling nano-gels, whose structure explains the conservation of the resistance of the network which can thus follow the deformations of the skin or the mucous membranes without peeling off or breaking. .
- a first object of the invention is a composition, in particular a cosmetic composition, a pharmaceutical composition or a medical device, comprising a water-soluble polymer (WSP) and particles of microgels, in which the particles of microgels and the water-soluble polymer can be independently obtained, or are independently obtained, by aqueous phase precipitation polymerization of di (ethylene glycol) methyl ether methacrylate, an oligo (ethylene glycol) methyl ether methacrylate, and a vinyl monomer bearing a carboxyl group, in the presence of N, N'-methylenebisacrylamide as a crosslinking agent, in which the ratio between the mass of the water-soluble polymer and the mass of the microgel particles in the dry state is between 0% and 100%.
- WSP water-soluble polymer
- the ratio between the mass of the water-soluble polymer and the mass of the microgel particles is between 0% and 35%, or between 35% and 100%.
- a second object of the invention is a method for the cosmetic treatment or the topical pharmaceutical treatment of the skin, nails, lips, mucous membranes or hair of a person, said method comprising a first step application of the cosmetic composition, of the pharmaceutical composition or of the medical device as defined above.
- a third object of the invention is a process for the preparation of the cosmetic composition, the pharmaceutical composition or the medical device, said process comprising a step of preparing a mixture of microgel particles and a soluble polymer. in water, said step comprising:
- Figure 1 is a graph of conformation of radius of gyration as a function of molar mass for MBA-WSP (red), OEGDA-WSP (blue), PEG35K (black). WSP comes from a synthesis with 2 mol% crosslinker. The dotted line is representative of a power law with an exponent of 0.6. The solid black line fits the MBA-WSP curve according to a power law of exponent 0.27.
- FIG. 3 represents the curve of the storage modulus G ′ and of the loss modulus G ′′ as a function of the frequency of an unpurified MBA film and an unpurified OEGDA film with different levels of crosslinking agent: 2 mole% and 8 mole%.
- Figure 4 is a table providing the mass composition of unpurified films, after synthesis.
- FIG. 5A represents the expansion viscosity as a function of time of unpurified MBA films and OEGDA films with different levels of crosslinking agent: 2% by mole and 8% by mole.
- Figure 5B is the elongation at break for MBA film and OEGDA film for different crosslink densities at 2 mole% and 8 mole%.
- Figure 6A shows the modulus of conservation G ′ and the modulus of loss G ′′ as a function of the frequency of a 2.0 mole% OEGDA-MG film with different levels of MG.
- Figure 6B is the modulus of conservation G "and the modulus of loss G" as a function of the frequency of a 2.0 mole% MBA-MG film with different levels of MG.
- Figure 8A is the expansion viscosity versus time curve for OEGDA-MG films at different MG contents.
- Figure 8B is the extensional viscosity versus time curve of OEGDA-MG films for different MG contents.
- FIG. 9 is a bar graph showing the elongation at break for MBA film and OEGDA film for different MG contents.
- FIG. 10A shows the extension viscosity versus time curve for pure OEGDA-MG films at different film forming temperatures.
- Figure 10B is a bar graph showing the elongation at break values for pure OEGDA-MG films at different film forming temperatures.
- FIG. 11 shows two images obtained by AFM atomic force microscopy of the upper surface of films of OEGDA-MG (left image) and of MBA-MG (right image).
- Figure 12 shows two AFM images of a cross section of films of OEGDA-MG (left image) and MBA-MG (right image).
- FIG. 13 shows two images obtained by AFM atomic force microscopy of the upper surface of films of OEGDA-MG (left image) and of MBA-MG (right image) subjected to an elongation of 30%.
- Figure 14 shows AFMs in topographic contrast and images of the LogDMT module: (a) AFM in topographic contrast and (b) LogDMT module for 2 mol% MBA-MG films containing 25% MG, (c) AFM in topographic contrast and (d) LogDMT modulus for 2 mol% MBA-MG films containing 50% MG; (e) AFM in topographic contrast and (f) LogDMT modulus for 2 mol% MBA-MG films containing 75% MG.
- microgel particles are a crosslinked polymer in the form of spherical particles having an average size which can vary from 100 nm to 1000 nm in the dry state (c ' that is to say containing less than 2% by mass of water), preferably between 100 nm and 500 nm, from 350 to 450 nm, even better still 400 nm.
- the hydrodynamic radial distribution function of the microgels measured at an angle of 60 ° and at a temperature of 20 ° C may be less than 1.1.
- the microgel of the invention can be obtained by copolymerization in aqueous phase of several monomers.
- the average size of the microgel particles can vary depending on whether they contain water or not.
- Microgels in the sense of the present description, can be in the form of an aqueous dispersion of "particles of microgels” or in the form of a film comprising particles of microgels as defined above.
- Microgels can trap cosmetic or pharmaceutical active organic molecules.
- a film comprising microgel particles can have a thickness of 1 micron to 10 millimeters, for example 10 microns to 500 microns, 100 microns to 400 microns or 500 microns to 1000 microns.
- the microgel particles preferably do not include any inorganic material.
- microgel particles consist of organic compounds.
- the microgel particles do not contain, for example, silica, in particular silica as a support for the crosslinked polymer.
- crosslink is a group (part of a molecule) which links the chains of copolymers together. This crosslink originates from a “crosslinker” molecule which is mixed with the monomers during the polymerization process of the crosslinked polymer.
- a "water-soluble polymer” is a polymer having a radius of gyration at 20 ° C which is from 5 nm to 80 nm, for example from 10 nm to 30 nm.
- the water soluble polymer may have an average molecular weight of 1 x 10 5 g. mol 1 to 1 x 10 6 g. mol 1 .
- the radius of gyration and the molecular mass can be measured by any method known to those skilled in the art, for example by size exclusion chromatography.
- a water soluble polymer is distinguished from microgel particles: for example microgel particles can be identified by atomic force microscopy (AFM) observation of a film made by drying an aqueous dispersion of microgel particles. On the contrary, no particle can be detected by AFM observation of films which are made by drying a solution of the water soluble polymer.
- AFM atomic force microscopy
- the first object of the invention relates to a composition, in particular a cosmetic composition, a pharmaceutical composition, or a medical device, comprising a polymer soluble in water and particles of microgels, said particles of microgels having an average diameter from 100 nm to 1000 nm in the dry state, wherein the microgel particles and the water soluble polymer can be independently obtained, or are independently obtained, by aqueous phase precipitation polymerization of at least the three following monomers, in the presence of a crosslinking agent:
- the two crosslinking agents that is to say at least the crosslinking agent used to prepare the particles of microgels or at least the crosslinking agent used for preparing the water soluble polymer
- at least one of the two crosslinking agents is N, N'-methylenebisacrylamide and where the ratio between the mass of the water soluble polymer and the mass of the particles of microgels in the dry state is between 0% and 100 % by mass.
- this device includes a mixture consisting of the water-soluble polymer, the microgels and optionally water.
- the solid content of the cosmetic composition, the solid content of the pharmaceutical composition, and the solid content of the mixture included in the medical device is preferably 1.5% to 100% by mass.
- the solid content may be greater than a percentage selected from the group consisting of 2%; 3%; 4%; 5%; 10%; 15%; 20%; 25%; 30 % ; 35%; 40%; 45% and 50% by mass.
- the solid content of the composition of the invention can be defined as the percentage by weight of the solid elements that it contains, in particular as equal to the sum of the percentage by weight of the microgels in the dry state, of the percentage by weight of the polymer soluble in water, and optionally a percentage of any other solid compound which would be present in the composition.
- the solid content can be the sum of the percentage of microgels in the dry state and the percentage of polymer which are contained in the mixture.
- the microgel particles and the water-soluble polymer comprise chains having monomer units of diethylene glycol methacrylate, monomer units of oligoethylene glycol methacrylate comprising from 6 to 10 ethylene glycol units, methacrylic acid monomer units, and crosslinks.
- the oligo (ethylene glycol) methyl ether methacrylate preferably comprises from 7 to 8 ethylene glycol units.
- the oligo (ethylene glycol) methyl ether methacrylate may have a number-average molar mass (Mn) of 400 g / mole to 600 g / mole, preferably 450 to 500 g / mole.
- the vinyl monomer is preferably a (meth) acrylic acid monomer.
- the microgel particles and the water-soluble polymer can be independently obtained by polymerization by aqueous phase precipitation of three monomers in the presence of a crosslinking agent.
- the precipitation polymerization step comprises contacting, in an aqueous phase, the three monomers described above and the crosslinking agent, at a temperature between 40 ° C and 90 ° C, preferably of the order 70 ° C.
- the process does not require the presence of a surfactant, such as SDS (sodium dodecyl sulfate), and the Polymerization can be initiated by the addition of a water soluble free radical initiator, for example potassium persulfate (KPS).
- KPS potassium persulfate
- the mole fraction of di (ethylene glycol) methyl ether methacrylate is 80 mole% to 90 mole%
- the mole fraction of oligo (ethylene glycol) methyl ether methacrylate is 5% by mole to 15% by mole
- the mole fraction of the vinyl monomer bearing a carboxyl group is from 2% by mole to 8% by mole
- the mole fraction of the crosslinking agent is from 0.5 to 10% by mole , the sum of the four mole fractions being equal to 100 mole%.
- the mole fractions can be defined as the mole fractions of the monomers which are used to prepare the microgel or the water soluble polymers.
- mole fractions can be defined as the mole fractions of the monomer units in the microgel or in the water soluble polymer which have been obtained from the reaction between the monomers.
- the mole fraction of the crosslinking agent can be from 0.5 mole% to 10 mole%, from 0.5 mole% to 8 mole%, from 1 mole% to 7 mole% or from 1.5 mole% to 6 mole%.
- the molar ratio (a: b) between the di (ethylene glycol) methyl ether methacrylate (a) and the oligo (ethylene glycol) methyl ether methacrylate (b) is preferably between 1: 1 and 20: 1, for example between 5: 1 and 10: 1.
- the (meth) acrylic acid monomer can be selected from the group consisting of methyl acrylic, methyl methacrylic, ethyl acrylic, ethyl methacrylic, n-butyl acrylic, and n-butyl methacrylic, methacrylic, itaconic or acrylic acids. Methacrylic acid is preferred.
- the oligo (ethylene glycol) methyl ether methacrylate can have a molecular mass between 200 g / mole and 600 g / mole, or between 300 g / mole and 550 g / mole or between 450 g / mole and 500 g / mole.
- the mole fraction of monomer units of di (ethylene glycol) methacrylate is 80 mole% to 90 mole%, preferably 82 mole% to 86 mole%
- the mole fraction of oligo (ethylene glycol) methyl ether methacrylate monomer units is 5 mole% to 15 mole%, preferably 7 mole% to 11 mole%
- the mole fraction of monomer units of (meth) acrylic acid is 2 mole% to 8 mole%, preferably 3 mole% to 7 mole%
- the mole fraction of the crosslink is 1 mole% to 6 mole% or 1 mol% to 3 mol%.
- the crosslinked polymer comprises copolymer chains having monomer units of diethylene glycol methacrylate, monomer units of oligoethylene glycol methacrylate comprising from 4 to 10 ethylene glycol units, and acid monomer units.
- methacrylic The monomer units are preferably: oligo (ethylene glycol) methyl ether methacrylate having 7 or 8 ethylene glycol units; and methacrylic acid.
- the monomer units of oligo (ethylene glycol) methyl ether methacrylate can also have 9 ethylene glycol units.
- the microgel is obtained by polymerization of at least three monomers, in the presence of a first crosslinking agent, and the water-soluble polymer is obtained from a polymerization of at least three monomers, in presence of a second crosslinking agent.
- the first crosslinking agent and / or the second crosslinking agent is N, N'-methylenebisacrylamide.
- one of the two crosslinking agents has di (meth) acrylate end groups and a unit chosen from the group consisting of - (CH 2 -CH 2 -0) m -CH 2 -CH 2 - where n is 0 to 6, -NH-CH 2 -NH- and mixtures thereof.
- the number m is preferably 3 to 6.
- One of the crosslinking agents is for example N, N'-methylenebisacrylamide (MBA) while the other is (ethylene glycol) dimethacrylate (EGDMA) or an oligo (ethylene glycol) diacrylate (OEGDA).
- MSA N, N'-methylenebisacrylamide
- EGDMA ethylene glycol dimethacrylate
- OEGDA oligo (ethylene glycol) diacrylate
- the first crosslinking agent and the second crosslinking agent are both N, N'-methylenebisacrylamide.
- the cosmetic composition, the pharmaceutical composition and the mixture included in the medical device are in the form of a film comprising microgels which are obtained with 1.8-2.2% by mole of N, N'-methylenebisacrylamide as a crosslinking agent.
- These films are advantageous because they are very flexible.
- the cosmetic composition, the pharmaceutical composition or the mixture which is included in the medical device is in the form of a film which has a thickness of 500 microns to 1000 microns.
- the ratio between the mass of the water-soluble polymer and the mass of the microgel particles is greater than 0% and less than 100%.
- the ratio may have a lower value which is chosen from the group consisting of 5%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% , 70%, 75%, 80%, 85%, 90% and 95%.
- the ratio may have a higher value which is chosen from the group consisting of 5%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65% , 70%, 75%, 80%, 85%, 90% and 95%.
- the ratio between the mass of the water-soluble polymer and the mass of the microgel particles is between 0% and 35%. In a second embodiment, the ratio between the mass of the water-soluble polymer and the mass of the microgel particles is between 35% and 100%.
- the cosmetic composition and the pharmaceutical composition can be a liquid, a gel or a solid.
- the cosmetic composition, the pharmaceutical composition or the mixture consisting of the polymer soluble in water, the microgels and optionally water which is included in the medical device may contain from 50% to 100% by mass of a mixture consisting of particles of microgels and polymer soluble in water, and from 0% to 50% by mass of water, the percentages being relative to the mass of the composition and the mass of the microgel particles being the mass of the particles in the dry state.
- the solid content of the cosmetic composition, the solid content of the pharmaceutical composition, and the solid content of the mixture consisting of the water soluble polymer, the microgels and optionally water which is included in the medical device can be from 50% to 100% by mass.
- the composition of the invention in the case where the composition of the invention is liquid, it can be spread on the skin or on the mucous membranes, and can form a transparent film adhering to the skin or to the mucous membranes by simple evaporation of the water.
- the skin has a low elastic modulus and that the product applied must have a modulus comparable to that of the skin so as not to be felt by the user.
- the free polymer is a lever for adjusting the modulus according to the intended application.
- the addition of components such as gelling agents or bioactants, can increase the modulus: it is then possible to add the proportion of free polymer agreed to reduce it to a target value.
- the films have a high elongation at break whatever the level of free polymer, which is essential for application to the face for example.
- the composition can comprise from 1% to 100% by mass of the microgels.
- the composition comprises according to one embodiment from 1% to 50% by mass of microgels relative to the mass of the composition, and from 0.9% to 100% by mass of water relative to the mass of the composition.
- the composition can be in the form of a dispersion of microgels in water.
- the aqueous dispersion may comprise from 1% to 50% by mass of a mixture consisting of microgels and water soluble polymer based on the mass of the composition, and from 50% to 99% by mass of water, based on the mass of the composition.
- the composition can be in the form of a film having a thickness of 1 micron to 10 millimeters comprising from 50% to 100% by mass of a mixture consisting of microgels and water-soluble polymer, and 0 % to 50% by mass of water, the percentages being expressed relative to the total mass of the composition.
- the films can be produced from an aqueous dispersion comprising the microgel and the water-soluble polymer, by evaporation of the water.
- the aqueous dispersion is for example spread on a rigid or flexible substrate, where the substrate has a temperature between 20 ° C and 60 ° C, even better a temperature of 30 ° C to 40 ° C, much better still a temperature equal to 35 ° C. ° C.
- the films can be formed by a step of placing in a mold a dispersion of particles of microgels in water and the water-soluble polymer, and by a step of drying the dispersion. Drying can be achieved by placing the mold at a temperature above room temperature, for example a temperature of 30 ° C to 60 ° C.
- the cosmetic composition can comprise at least one component chosen from the group consisting of preservatives, perfumes, emollients, surfactants, oils, biologically active products, pigments and dyes.
- the method of the invention comprises a first step of preparing microgels, a second step of preparing the water-soluble polymer and a third step of mixing the two.
- the method for the preparation of a cosmetic composition, of a pharmaceutical composition or of a medical device as described above can comprise a step of preparing a mixture of particles of microgels and of a soluble polymer. in water, said step comprising a first step and a second step which may be successive, in any order, or simultaneous:
- said first step being a step of preparing microgel particles, and comprising a step (i) of polymerization by precipitation in aqueous phase of at least the following three monomers, in the presence of a first crosslinking agent: di (ethylene glycol) methyl ether methacrylate, an oligo (ethylene glycol) methyl ether methacrylate, a vinyl monomer bearing a carboxyl group, and a purification step (ii) to recover the microgel particles which were obtained at the end of step (i),
- said second step of preparing the water-soluble polymer comprising a step (a) of polymerization by precipitation in aqueous phase of at least the following three monomers, in the presence of a second crosslinking agent: di (ethylene glycol) methyl ether methacrylate, an oligo (ethylene glycol) methyl ether methacrylate, a vinyl monomer bearing a carboxyl group, and a purification step (b) to recover the water-soluble polymer which was obtained at the end of the step (a), in which at least the first or the second crosslinking agent is N, N'-methylenebisacrylamide,
- a third step which follows said first step and said second step, said third step being a step of mixing a mass of particles of purified microgels which have been obtained at the end of said first step, and a mass of water-soluble polymer which is obtained at the end of said second step, where the ratio between the mass of the water-soluble polymer and the dry mass of the microgel particles is between 0% and 100%.
- Step (ii) can comprise at least one centrifugation / redispersion cycle to separate the precipitate and the supernatant, and a step of recovering the microgel particles in the precipitate.
- step (b) can include at least one centrifugation / redispersion cycle to separate the precipitate and the supernatant, and a step of recovering the water-soluble polymer from the supernatant.
- the first step and the second step are a single step, so that particles of microgels and a water-soluble polymer are produced at the same time from the same monomers, in which the single step comprises at least one centrifugation / redispersion cycle to separate the precipitate and the supernatant which has been obtained from the aqueous phase precipitation polymerization of the monomers, said microgel particles being recovered in the precipitate, and said water soluble polymer being recovered in the supernatant.
- the ratio between the mass of the water soluble polymer in the supernatant, and the mass of the microgel particles in the precipitate is a first ratio and, in the third step, the ratio between the mass of the water soluble polymer and the mass of the microgel particles is a second ratio which is between 0% and 100% and which is different from the first ratio.
- the first crosslinking agent and the second crosslinking agent are preferably both N, N'-methylenebisacrylamide, although one of them may be different from this.
- the invention also relates to a method of topical cosmetic or pharmaceutical treatment of the skin, nails, lips, mucous membranes or hair of a person, said method comprising a first step of application to the person. of a composition or a medical device as described above.
- the method may include a second step of drying the composition or device that has been applied to the person to obtain a flexible, cohesive and adhesive film.
- Poly (oligo- (ethylene glycol) methacrylate) microgels, water-soluble polymers, and films comprising the mixture of these microgels and water-soluble polymers were prepared according to the following protocol. Their rheology (linear and non-linear) was studied and their structure observed by atomic force microscopy (AFM).
- AFM atomic force microscopy
- ME02MA (92.6 mmol), OEGMA (10.3 mmol) and a crosslinker (OEGDA or MBA) were dissolved in 930 g of water.
- the crosslinker ratios are set either at 2.0% by mole or at 8.0% by mole depending on the total of the vinyl molecules, corresponding respectively to 2.12 mmol and 9.42 mmol.
- the mixture is introduced into the 2 L reactor and the stirring is set at 150 rpm.
- the reactor is purged with nitrogen for 45 min to remove oxygen at room temperature.
- MAA (5.41 mmol) is dissolved in 30 g of water and added to the reactor.
- the mixture is then heated to 70 ° C.
- KPS (0.958 mmol) is dissolved in 40 g of water and inserted into the reactor to start the reaction.
- the reaction is finally maintained at 70 ° C for 6 hours.
- a first part of the aqueous suspension comprising MG and WSP is obtained and the films (F6, F6 ', F7 and F7') are formed.
- a second part of the aqueous suspension is separated by 3 cycles of centrifugation (20,000 rev / m, 20 min), where WSP is maintained in the aqueous supernatant while MG is found in the precipitate.
- Films with WSP alone (F5 and F5 ') and films with MG alone (Fl and Fl') are formed as comparative films.
- Films comprising a mixture of WSP and MG in a predetermined ratio are also prepared (F2, F2 ', F3, F3', F4 and F4 ').
- Films were formed by the direct evaporation of water from solutions of microgels in a glass bell oven heated to 37 ° C. It has been shown that the formation temperature does not influence the properties of the film. We used silicone molds as containers for easy removal of films after drying. For rheological experiments, the final film thicknesses are between 500 microns and 1000 microns. All thicknesses less than and greater than these values are nevertheless technically feasible, for example as low as 500 nm.
- the steric exclusion chromatography (SEC) apparatus consists of a set of aqueous columns from Shodex and an Agilent 1260 Iso pump from Agilent technologies.
- the device is coupled with a Multi Angle Light Scattering (MALS) and a differential refractometer (RI) detector.
- MALS detector used is a Dawn Heleos detector from WYATT Technology.
- RI detector is an Optilab T-rEX from WYATT Technology operating at a laser wavelength of 664 nm.
- the flow rate is set during the experiment at 0.5 mL / min and the column temperature is set at 30 ° C.
- the mobile phase consists of a solution of NaNCh at 0.1 g / mole (8.2 g / L), and sodium azide NaN 3 (0.1 mol / L) as eluent, stabilized with a buffer at pH 8.
- the mobile phase is filtered at 0.1 ⁇ m before use.
- the water-soluble polymer solutions are prepared at a concentration of 200 ppm in a buffer of pH 8, of which a volume of 100 ⁇ L is injected.
- the solutions are filtered before use at 250 nm to remove any impurities and possible microgels.
- the value of the refractive index increment (dn / dc) is experimentally measured on an Optilab T-rEX refractometer from WYATT Technology with a laser wavelength of 532 nm.
- Five WSP solutions are prepared with Milli-Q water at different concentrations (0.97 gL 1 ; 0.75 gL 1 ; 0.51 gL 1 and 0.11 gL 1 ).
- the size exclusion chromatography makes it possible to determine the molar mass of WSP from a synthesis of 2 mol% OEGDA and a synthesis of 2 mol% MBA. This technique has the advantage of measuring both molecular mass and radius of gyration. It thus provides more information about the structure of WSP.
- OEGDA-WSP and MBA-WSP are compared to a linear PEG with an average molecular weight of 35,000 g. mol 1 .
- Molar mass and radius of gyration are related by Flory's theory.
- FIG. 1 represents the graph of conformity that is to say the radius of gyration as a function of the molecular mass for OEGDA-WSP, MBA-WSP and PEG 35K.
- Figure 2 summarizes the molecular weights and polydispersity index of OEGDA-WSP, MBA-WSP and PEG 35K.
- PEG 35K exhibits an average Mw at 34,000 g. mol 1 which validates the reliability of the method used.
- As the polymer has a very narrow mass distribution, it is not possible to observe the change in the radius of gyration as a function of molecular weight.
- OEGDA-WSP and MBA-WSP share a similar population of molecular weights from 1 x 10 4 to 1 x 10 5 g.
- Some films are formed from the aqueous suspension comprising MG and WSP which is obtained from the aqueous precipitation polymerization process, before any centrifugation step.
- MG microgel
- WSP water soluble polymer
- the films are characterized by linear oscillatory rheology and non-linear extensional rheology on an MCR 302 rheometer from Anton Paar.
- Oscillatory rheology is carried out on films approximately 1 mm thick with parallel 8 mm plates at controlled temperature. Frequency sweeps are performed at 20 ° C from 0.01 to 600 rad / s at constant 1% elongation which ensures linear speed.
- Extension rheology is performed using SER (Sentmanat Extension Rheometer) geometry which consists of paired winding drums moving in equal but opposite rotation. The tests are carried out at 20 ° C.
- the film dimensions are in the following range: 0.5-1mm x 1-2mm x 15-20mm.
- the thickness and the width are before the test respectively measured by optical microscopy and compass.
- Films are stretched to break with a constant elongation rate, also cited as the Hencky eH elongation rate. A minimum of fifty samples are tested for each type of film.
- the extensional viscosity hE is measured as a function of time.
- the logarithmic elongation in the sample is a function of e, of the constant rate of elongation; t, time; L is the sample length at time t and L0 is the initial sample length.
- the constant elongation rate is multiplied by the time at break.
- the impact of the formation temperature was evaluated by forming films purified at 20 ° C, 32 ° C, 37 ° C and 60 ° C.
- the object was to evaluate whether the state of the microgels, that is to say collapsed or swollen, impacts the quality of the assembly during the formation of the film. Indeed, during the liquid-to-solid transition, one can imagine that the state of the microgel can play an important role, that is to say that the microgels inflated under the VPTT would create more intra-tangles than microgels collapsed above the VPTT.
- the extensional viscosity was measured at 20 ° C with a constant elongation rate of 0.5 s 1 .
- Figure 10 shows the average extensional viscosity for four different formation temperatures. It is clearly observed that the formation temperature does not impact the extensional viscosity or the elongation at break. It is not a parameter controlling the mechanical properties of films. If the microgels are under the VPTT (20 ° C), in the range (32 ° C, 37 ° C) or above (60 ° C), the elongation at break remains equal to 133 plus or minus 2 %. The microgel bark appears to retain some mobility at 60 ° C which allows the microgels to interpenetrate each other in their collapsed state. In addition, the microgel films, once formed, are maintained at 20 ° C and tested at 20 ° C. The chains thus have time to relax and reach a similar state of interpenetration regardless of the formation temperature.
- Figure 4 shows the ratio of water soluble polymer and microgels of the different films that were prepared.
- modulus of films of 8 mol% of MBA increases considerably compared to 2 mol% of crosslinking agent, respectively approximately 1.5 x 10 6 Pa and 1 x 10 5 Pa at 1 Hz (6 rad / s) .
- An 8 mol% OEGDA film surprisingly demonstrates moduli very similar to 2 mol% films. This particular behavior could be explained by a higher quantity of water in the film at the time of the test, due to the environment of uncontrolled hygrometry or to incomplete drying of the film.
- Extension rheology consists of the elongation of materials in the non-linear domain of deformations, at a constant rate of elongation. Uniaxial extension can produce a much higher degree of molecular orientation and stretch than a simple tear. Therefore, extension rheology is more sensitive to polymer long chain branching and may be more descriptive than other types of bulk rheology tests. Extensional rheology makes it possible to establish a relationship with adhesive behavior.
- FIG. 5 shows the mean extensional viscosity as a function of time of MBA and OEGDA for the two levels of crosslinking agent.
- the extensional viscosity increases permanently following the linear viscoelastic envelope defined by the slope of 3 times the complex viscosity: 3.rf.
- the extensional viscosity begins to deviate upwards from the shear viscosity. at zero speed. This upward deflection is referred to as elongation-cure and conventionally occurs in chemically crosslinked or physically well-entangled polymers. It is an indicative aspect of the branching chain architecture. The chain entanglements begin to resist extension whenever the chain extensibility limit is approached and cause the network to stiffen. Therefore, the extensional viscosity follows an upward deviation. The appearance of elongation-hardening was expected since the films contained 2 mole% and 8 mole% of crosslinker, respectively. Elongation-cure has been considered a desirable property for better adhesive performance. It fulfills the typical requirement for an adhesive that fails without leaving a sticky residue on the surface by providing cohesion to the network at high strain.
- OEGDA and MBA films exhibit similar behavior in the linear region.
- the elongation at break is however significantly higher for MBA than OEGDA regardless of the crosslinker density, FIG. 5 (image on the left).
- FIG. 5 image on the left.
- the increased crosslink density leads to a lower elongation at break for both crosslinkers. Indeed, a more reticulated network cannot stretch as much to adapt to the stress, and break at a less advanced stage. More dense and more crosslinked particles also tend to interpenetrate less with each other, thus creating a weaker lattice.
- FIG. 8 shows the mean extensional viscosity as a function of time of MBA and OEGDA for different MG contents.
- the extensional viscosity begins to deviate upward from the zero speed shear viscosity for all formulations. As previously mentioned, this upward deflection is called elongation-hardening.
- the appearance of elongation-cure for 100% MG films is expected since the films contained 2 mole% crosslinker providing crosslinked spots to the network. More surprisingly, however, all films, including 100% WSP, exhibit elongation-cure.
- network stiffening is much more related by chemical crosslinking points than physical branching chain entanglements.
- the microgel content has a large impact on the extensional viscosity values. This is because microgels act as matrix stiffening fillers, and increase the G ’and G’ moduli. As a direct consequence, the higher moduli increase the extension viscosity value.
- Fig. 9 The second An important result of Fig. 9 is that the MBA films made from 100% WSP also exhibit a higher elongation at break than the OEGDA-WSP films. This corroborates the SEC results which show a more branched structure in the case of MBA-WSP.
- Method Topographic images were captured by AFM (Bruker Multi mode 8 apparatus) in order to analyze the assembly of microgels on the film surface. Peak Force QNM Air mode and ScanAsyst Air probes (mean spring constant k of 0.4 Nm 1 ) were used for all scans. Clean cross sections of microgel films were also prepared to visualize the assembly within the film, with a Leica EM UC7 ultra cryo-microtome apparatus, using a Leica EM-FC7 cryo-chamber, cooled to -80 ° C. Finally, the films were manually subjected to unidirectional stretching and images were formed in the stretched state. The elongation corresponded to 30%.
- the cross sections of films were surface treated by ultra cryomicrotomy and observed by AFM.
- the topographic contrast images in Figure 12 show the settlement of spherical particles with localized hexagonal settlement.
- the several layers of MG stacking during the evaporation of the solvent has not flattened out and remains spherical.
- a contrast difference of about 15 nm between core and bark is observed for most microgels in both types of crosslinkers.
- the microgel films contain and absorb water from their surroundings. As a result, it can be suggested that the bark, which is much more swollen, is loosely reticulated and the core, which is more hollow, is more reticulate than the bark.
- Microgel films were stretched to obtain 30% elongation and their upper surfaces were observed by AFM.
- Figure 13 shows a 5mm topographic contrast image of OEGDA-crosslinked and MBA-crosslinked microgel films.
- the direction of stretching is parallel to the X axis. Stretching causes loss of hexagonal compact settlement and deformation of the particle network. Gaps appear between the microgels in the direction of deformation. However, it seems that the microgels are not significantly deformed and maintain their spherical shape. It is suggested that at this elongation most of the tangled chains of the microgel bark stretch to accommodate the stress and the dense core is not yet deformed.
- Figure 14 shows the 2 micron topographic contrast image (a) and logDMT modulus (b) of 2 mol% MBA-MG to 25 mass% MG films.
- the logDMT module channel has the steepest regions in lighter color and the softer regions in darker color.
- the microgels are much denser than the water soluble polymer and look like fillers dispersed in a flexible composite matrix. They do not form aggregates but are not perfectly dispersed homogeneously.
- Figure 14 shows the 2 micron topographic contrast image (c) and logDMT modulus (d) of 2 mol% MBA-MG to 50 mass% MG films.
- microgels start to come into contact with each other but no structured arrangement is observed. In some areas, microgel depletion is observed.
- figure 14 is presented the topographic contrast image of 500 nm (e) and logDMT modulus (f) of MBA-MG films for 75% by mass of MG. Similar conclusions can be expressed, the microgels are closer but no hexagonal packing arrangement is observed.
- the core / shell structure is clearly observed with a clear modulus gradient between the core relative to the WSP matrix.
- the denser and less swollen hearts are characterized by hollows, the rinds are more swollen than the hearts but slightly denser than the water soluble polymer which is characterized by the lower modulus.
- a very gradual transition is observed between the microgel shell and the water soluble polymer, suggesting a similar structure as well as some interpenetration between the two phases.
- Linear rheology on 2 mol% OEGDA and MBA-crosslinked microgel films demonstrates that the shear modulus value can vary and be adjusted via the water soluble polymer content, from 0% to 100%. As a result, it is possible to form a range of very tacky films up to films not exhibiting tackiness on any substrate by the simple evaporation of water. Microgel films exhibit interesting mechanical properties at high strain. The elongation at break is up to 60%, demonstrating that these films exhibit strong cohesion for a simple and spontaneous self-assembled particle network. In addition, the variation of the water-soluble polymer makes it possible to vary the rheological properties without modifying the stretch properties of the films.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1914551A FR3104419B1 (fr) | 2019-12-16 | 2019-12-16 | Composition ou dispositif médical comprenant des polymères à base d'oligo(éthylène glycol) |
| PCT/FR2020/052213 WO2021123532A1 (fr) | 2019-12-16 | 2020-11-27 | Composition ou dispositif médical comprenant des polymères à base d'oligo(éthylène glycol) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4076339A1 true EP4076339A1 (fr) | 2022-10-26 |
Family
ID=70804645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20824611.6A Pending EP4076339A1 (fr) | 2019-12-16 | 2020-11-27 | Composition ou dispositif médical comprenant des polymères à base d'oligo(éthylène glycol) |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230069954A1 (fr) |
| EP (1) | EP4076339A1 (fr) |
| FR (1) | FR3104419B1 (fr) |
| WO (1) | WO2021123532A1 (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3005226T3 (en) * | 2015-01-06 | 2025-03-14 | Lvmh Rech | Cosmetic or pharmaceutical product containing poly(ethylene glycol methacrylate) microgels |
| EP3473236B1 (fr) | 2017-10-17 | 2021-04-28 | LvmH Recherche | Microgels pour administration de substances organiques actives cosmétiques |
| CN108250358B (zh) * | 2018-02-06 | 2020-02-04 | 西北师范大学 | 一种负载微凝胶的多重响应性水凝胶的制备方法 |
| JP6991490B2 (ja) * | 2019-06-07 | 2022-02-03 | エルヴェエムアッシュ ルシェルシュ | ポリ(エチレングリコール)メタクリレートミクロゲル、調製方法および使用 |
-
2019
- 2019-12-16 FR FR1914551A patent/FR3104419B1/fr active Active
-
2020
- 2020-11-27 EP EP20824611.6A patent/EP4076339A1/fr active Pending
- 2020-11-27 US US17/784,507 patent/US20230069954A1/en active Pending
- 2020-11-27 WO PCT/FR2020/052213 patent/WO2021123532A1/fr not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| GARBI�E AGUIRRE ET AL: "Supporting Information Smart self-assembled microgel films as encapsulating carriers for UV-absorbing molecules", 16 February 2018 (2018-02-16), XP055711562, Retrieved from the Internet <URL:http://www.rsc.org/suppdata/c8/py/c8py00146d/c8py00146d1.pdf> [retrieved on 20200703] * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021123532A1 (fr) | 2021-06-24 |
| US20230069954A1 (en) | 2023-03-09 |
| FR3104419A1 (fr) | 2021-06-18 |
| FR3104419B1 (fr) | 2025-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yusa et al. | Synthesis of well-defined amphiphilic block copolymers having phospholipid polymer sequences as a novel biocompatible polymer micelle reagent | |
| EP1051436B1 (fr) | Nouveaux copolymeres tensioactifs a base de methylidene malonate | |
| EP1169354B1 (fr) | Microparticules reticulees, leur procede de preparation et applications | |
| Zhang et al. | Morphological stabilization of block copolymer worms using asymmetric cross-linkers during polymerization-induced self-assembly | |
| Roy et al. | Remarkable swelling capability of amino acid based cross-linked polymer networks in organic and aqueous medium | |
| Yusa et al. | Reversible pH-induced formation and disruption of unimolecular micelles of an amphiphilic polyelectrolyte | |
| WO1995009874A1 (fr) | Microdispersions stables et microgels a base de polymeres acryliques, leur procede d'obtention et compositions, notamment cosmetiques, les contenant | |
| van Westerveld et al. | Effect of polyelectrolyte charge density on the linear viscoelastic behavior and processing of complex coacervate adhesives | |
| FR3016885A1 (fr) | Copolymeres thermoassociatifs et echangeables, compositions les comprenant | |
| Miasnikova et al. | Thermoresponsive hydrogels from symmetrical triblock copolymers poly (styrene-block-(methoxy diethylene glycol acrylate)-block-styrene) | |
| EP3980471B1 (fr) | Procede de preparation de polymeres structures sous forme de poudre par voie gel | |
| Kataoka et al. | Fast and reversible cross-linking reactions of thermoresponsive polymers based on dynamic dialkylaminodisulfide exchange | |
| FR2744125A1 (fr) | Copolymeres greffes, leur procede de fabrication, les compositions les contenant et leur utilisation pour la preparation de dispersions pigmentaires en milieu aqueux et/ou organique | |
| JP2019518854A (ja) | ナノゲルによるポリマーネットワーク構造の制御 | |
| Ida et al. | Swelling and mechanical properties of thermoresponsive/hydrophilic conetworks with crosslinked domain structures prepared from various triblock precursors | |
| CN107406556A (zh) | 作为用于不良水溶性物质从固体混合物有效增溶的赋形剂的共聚物 | |
| Pitsikalis et al. | Micellization of model graft copolymers in dilute solution | |
| EP0783530B1 (fr) | Vernis a ongles contenant des microgels | |
| EP4076338A1 (fr) | Composition ou dispositif médical comprenant des polymères a base d'oligo(ethylène glycol) | |
| EP1409571B1 (fr) | Compositions aqueuses comprenant un microgel chimique associe a un polymere aqueux | |
| Morimoto et al. | Botryoidal assembly of cholesteryl− pullulan/poly (N-isopropylacrylamide) nanogels | |
| Woods et al. | Temperature-responsive lactic acid-based nanoparticles by RAFT-mediated polymerization-induced self-assembly in water | |
| EP2655454B1 (fr) | Particules polymeriques filementeuses et leur utilisation comme modificateurs de rheologie | |
| EP4076339A1 (fr) | Composition ou dispositif médical comprenant des polymères à base d'oligo(éthylène glycol) | |
| Schreur-Piet et al. | Amphiphilic statistical copolymers from catalytic chain transfer as reactive surfactants in emulsion polymerization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220621 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250516 |